# SOST

## Overview
The SOST gene encodes sclerostin, a secreted glycoprotein that plays a pivotal role in bone metabolism. Sclerostin is primarily expressed in osteocytes, the most abundant cells in bone, and functions as a key regulator of bone formation by antagonizing the Wnt signaling pathway. This protein is characterized by a cystine-knot motif, which is crucial for its structural stability and function as a Wnt signaling antagonist (Piters2010First; Brunkow2001Bone). By binding to the LRP5/6 co-receptors, sclerostin inhibits the Wnt/β-catenin signaling pathway, thereby modulating osteoblast activity and bone homeostasis (MartínezGil2021Genetics; Li2005Sclerostin). Additionally, sclerostin acts as a bone morphogenetic protein (BMP) antagonist, further influencing bone density and structure (Winkler2003Osteocyte). Mutations in the SOST gene are associated with bone disorders such as sclerosteosis and Van Buchem disease, highlighting its clinical significance in both excessive bone growth and osteoporosis (MartínezGil2021Genetics; Balemans2001Increased).

## Structure
The SOST gene encodes sclerostin, a protein characterized by a cystine-knot motif, which is a structural feature involving six cysteine residues forming disulfide bonds crucial for protein folding and stability (Piters2010First; Brunkow2001Bone). The primary structure of sclerostin includes a putative secretion signal and two N-glycosylation sites, indicating that it is a secreted glycoprotein (Brunkow2001Bone). The cystine-knot motif is located within a cysteine-rich region covering residues 80-167, similar to proteins such as gastric mucin and the beta subunit of luteinizing hormone (Brunkow2001Bone).

Sclerostin's tertiary structure is stabilized by these disulfide bonds, and the protein's folding is essential for its function as a Wnt signaling antagonist (Piters2010First). The mutation of cysteine to arginine at position 167 disrupts one of these disulfide bonds, leading to misfolding and impaired secretion (Piters2010First). Sclerostin is part of the DAN family of BMP antagonists, sharing structural similarities with other family members, although it lacks a cystine residue involved in dimerization found in other DAN proteins (Bezooijen2005SOSTsclerostin). The protein is primarily expressed in osteocytes and plays a significant role in bone homeostasis by inhibiting the Wnt signaling pathway (Yavropoulou2014The).

## Function
The SOST gene encodes sclerostin, a protein primarily expressed in osteocytes, which are cells embedded within the bone matrix. Sclerostin plays a crucial role in bone metabolism by acting as an antagonist to the Wnt signaling pathway, which is essential for bone formation. It achieves this by binding to the LRP5/6 co-receptors, thereby inhibiting the pathway and reducing osteoblast activity, which are the cells responsible for bone synthesis (MartínezGil2021Genetics; Li2005Sclerostin). This regulatory mechanism is vital for maintaining bone homeostasis and preventing excessive bone formation (Winkler2003Osteocyte).

Sclerostin also functions as a bone morphogenetic protein (BMP) antagonist, competing with BMP receptors and inhibiting BMP signal transduction. This action further modulates osteoblastic function by reducing the expression of osteoblastic markers and inhibiting the mineralization of mesenchymal stem cells (Winkler2003Osteocyte). The protein's role in these molecular processes ensures the maintenance of normal bone density and structure, preventing conditions characterized by excessive bone growth, such as sclerosteosis (Brunkow2001Bone). In healthy human cells, sclerostin's function is essential for balancing bone formation and resorption, contributing to overall skeletal health (Piters2010First).

## Clinical Significance
Mutations and alterations in the SOST gene, which encodes the protein sclerostin, are linked to several bone disorders. Sclerosteosis is a severe autosomal recessive condition caused by loss-of-function mutations in the SOST gene, leading to excessive bone formation and increased bone density (Balemans2001Increased; Brunkow2001Bone). This condition is characterized by generalized hyperostosis and sclerosis, resulting in thickened and sclerotic bones (Balemans2001Increased). Van Buchem disease, another condition associated with the SOST gene, results from a deletion of a regulatory region downstream of the gene, leading to low levels of sclerostin and excessive bone growth (MartínezGil2021Genetics).

Alterations in SOST expression are also implicated in osteoporosis, particularly postmenopausal osteoporosis. Reduced SOST expression, often due to DNA methylation, is associated with decreased bone mineral density and increased fracture risk in postmenopausal women (Reppe2014Methylation; Shan2019Methylation). The SOST gene's role in bone metabolism makes it a target for osteoporosis treatments, with humanized monoclonal antibodies against sclerostin being used to increase bone mass and strength (MartínezGil2021Genetics). These findings highlight the clinical significance of SOST in both excessive bone growth disorders and conditions of reduced bone density.

## Interactions
Sclerostin, encoded by the SOST gene, is a protein that primarily interacts with components of the Wnt signaling pathway. It binds to the low-density lipoprotein receptor-related proteins 5 and 6 (LRP5/6), acting as an antagonist to Wnt/β-catenin signaling, which is crucial for bone formation and maintenance (DelgadoCalle2017Role). Sclerostin inhibits Wnt signaling by interacting with the LRP6 ectodomains, specifically the E1 and E2 domains, through its loop 2 and C-terminal regions. This interaction blocks the signaling of various Wnt proteins, such as Wnt1, Wnt2, and Wnt9b, but not Wnt3a, due to differences in binding affinities (Kim2020Sclerostin).

Sclerostin also interacts with bone morphogenetic proteins (BMPs), acting as a BMP antagonist. It binds to BMPs, such as BMP-5 and BMP-6, with high affinity, competing with BMP receptors and inhibiting BMP signaling. This interaction decreases BMP-stimulated SMAD phosphorylation, a key step in BMP signaling, thereby modulating osteoblastic function and bone formation (Winkler2003Osteocyte). These interactions highlight sclerostin's role in regulating bone metabolism and its potential as a therapeutic target for bone-related disorders.


## References


[1. (Yavropoulou2014The) Maria Yavropoulou, Christos Xygonakis, Maria Lolou, Fotini Karadimou, and John Yovos. The sclerostin story: from human genetics to the development of novel anabolic treatment for osteoporosis. HORMONES, December 2014. URL: http://dx.doi.org/10.14310/horm.2002.1552, doi:10.14310/horm.2002.1552. This article has 9 citations and is from a peer-reviewed journal.](https://doi.org/10.14310/horm.2002.1552)

[2. (MartínezGil2021Genetics) Núria Martínez-Gil, Neus Roca-Ayats, Mónica Cozar, Natàlia Garcia-Giralt, Diana Ovejero, Xavier Nogués, Daniel Grinberg, and Susanna Balcells. Genetics and genomics of sost: functional analysis of variants and genomic regulation in osteoblasts. International Journal of Molecular Sciences, 22(2):489, January 2021. URL: http://dx.doi.org/10.3390/ijms22020489, doi:10.3390/ijms22020489. This article has 7 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms22020489)

[3. (Li2005Sclerostin) Xiaofeng Li, Yazhou Zhang, Heeseog Kang, Wenzhong Liu, Peng Liu, Jianghong Zhang, Stephen E. Harris, and Dianqing Wu. Sclerostin binds to lrp5/6 and antagonizes canonical wnt signaling. Journal of Biological Chemistry, 280(20):19883–19887, May 2005. URL: http://dx.doi.org/10.1074/jbc.m413274200, doi:10.1074/jbc.m413274200. This article has 1092 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.m413274200)

[4. (Winkler2003Osteocyte) D. G. Winkler. Osteocyte control of bone formation via sclerostin, a novel bmp antagonist. The EMBO Journal, 22(23):6267–6276, December 2003. URL: http://dx.doi.org/10.1093/emboj/cdg599, doi:10.1093/emboj/cdg599. This article has 899 citations.](https://doi.org/10.1093/emboj/cdg599)

[5. (Reppe2014Methylation) Sjur Reppe, Agate Noer, Runa M Grimholt, Bjarni V Halldórsson, Carolina Medina-Gomez, Vigdis T Gautvik, Ole Kristoffer Olstad, Jens Petter Berg, Harish Datta, Karol Estrada, Albert Hofman, André G Uitterlinden, Fernando Rivadeneira, Robert Lyle, Philippe Collas, and Kaare M Gautvik. Methylation of bone sost, its mrna, and serum sclerostin levels correlate strongly with fracture risk in postmenopausal women. Journal of Bone and Mineral Research, 30(2):249–256, August 2014. URL: http://dx.doi.org/10.1002/jbmr.2342, doi:10.1002/jbmr.2342. This article has 85 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1002/jbmr.2342)

[6. (Balemans2001Increased) W. Balemans. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (sost). Human Molecular Genetics, 10(5):537–543, March 2001. URL: http://dx.doi.org/10.1093/hmg/10.5.537, doi:10.1093/hmg/10.5.537. This article has 938 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1093/hmg/10.5.537)

[7. (Shan2019Methylation) Yu Shan, Liang Wang, Guangfei Li, Guangsi Shen, Peng Zhang, and Youjia Xu. Methylation of bone sost impairs sp7, runx2, and erα transactivation in patients with postmenopausal osteoporosis. Biochemistry and Cell Biology, 97(4):369–374, August 2019. URL: http://dx.doi.org/10.1139/bcb-2018-0170, doi:10.1139/bcb-2018-0170. This article has 17 citations.](https://doi.org/10.1139/bcb-2018-0170)

[8. (Bezooijen2005SOSTsclerostin) Rutger L. van Bezooijen, Peter ten Dijke, Socrates E. Papapoulos, and Clemens W. G.M. Löwik. Sost/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine &amp; Growth Factor Reviews, 16(3):319–327, June 2005. URL: http://dx.doi.org/10.1016/j.cytogfr.2005.02.005, doi:10.1016/j.cytogfr.2005.02.005. This article has 288 citations.](https://doi.org/10.1016/j.cytogfr.2005.02.005)

[9. (Kim2020Sclerostin) Jinuk Kim, Wonhee Han, Taeyong Park, Eun Jin Kim, Injin Bang, Hyun Sik Lee, Yejin Jeong, Kyeonghwan Roh, Jeesoo Kim, Jong-Seo Kim, Chanhee Kang, Chaok Seok, Jin-Kwan Han, and Hee-Jung Choi. Sclerostin inhibits wnt signaling through tandem interaction with two lrp6 ectodomains. Nature Communications, October 2020. URL: http://dx.doi.org/10.1038/s41467-020-19155-4, doi:10.1038/s41467-020-19155-4. This article has 49 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-020-19155-4)

[10. (DelgadoCalle2017Role) Jesus Delgado-Calle, Amy Y. Sato, and Teresita Bellido. Role and mechanism of action of sclerostin in bone. Bone, 96:29–37, March 2017. URL: http://dx.doi.org/10.1016/j.bone.2016.10.007, doi:10.1016/j.bone.2016.10.007. This article has 330 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.bone.2016.10.007)

[11. (Piters2010First) Elke Piters, Cavit Culha, Martiene Moester, Rutger Van Bezooijen, Dirk Adriaensen, Thomas Mueller, Stella Weidauer, Karen Jennes, Fenna de Freitas, Clemens Löwik, Jean-Pierre Timmermans, Wim Van Hul, and Socrates Papapoulos. First missense mutation in the sost gene causing sclerosteosis by loss of sclerostin function. Human Mutation, 31(7):E1526–E1543, May 2010. URL: http://dx.doi.org/10.1002/humu.21274, doi:10.1002/humu.21274. This article has 50 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/humu.21274)

[12. (Brunkow2001Bone) Mary E. Brunkow, Jessica C. Gardner, Jeff Van Ness, Bryan W. Paeper, Brian R. Kovacevich, Sean Proll, John E. Skonier, L. Zhao, P.J. Sabo, Ying-Hui Fu, Reid S. Alisch, Lucille Gillett, Trenton Colbert, Paolo Tacconi, David Galas, Herman Hamersma, Peter Beighton, and John T. Mulligan. Bone dysplasia sclerosteosis results from loss of the sost gene product, a novel cystine knot–containing protein. The American Journal of Human Genetics, 68(3):577–589, March 2001. URL: http://dx.doi.org/10.1086/318811, doi:10.1086/318811. This article has 817 citations.](https://doi.org/10.1086/318811)